Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082654025> ?p ?o ?g. }
- W3082654025 endingPage "499" @default.
- W3082654025 startingPage "485" @default.
- W3082654025 abstract "Leukemia, most commonly B-cell acute lymphoblastic leukemia (B-ALL), accounts for about 30% of childhood cancer diagnoses. While there have been dramatic improvements in childhood ALL outcomes, certain subgroups—particularly those who relapse—fare poorly. In addition, cure is associated with significant short- and long-term side effects. Given these challenges, there is great interest in novel, targeted approaches to therapy. A number of new immunotherapeutic agents have proven to be efficacious in relapsed or refractory disease and are now being investigated in frontline treatment regimens. Blinatumomab (a bispecific T-cell engager that targets cluster of differentiation [CD]-19) and inotuzumab ozogamicin (a humanized antibody–drug conjugate to CD22) have shown the most promise. Chimeric antigen receptor T (CAR-T) cells, a form of adoptive immunotherapy, rely on the transfer of genetically modified effector T cells that have the potential to persist in vivo for years, providing ongoing long-term disease control. In this article, we discuss the clinical biology and treatment of B-ALL with an emphasis on the role of immunotherapy in overcoming the challenges of conventional cytotoxic therapy. As immunotherapy continues to move into the frontline of pediatric B-ALL therapy, we also discuss strategies to address unique side effects associated with these agents and efforts to overcome mechanisms of resistance to immunotherapy." @default.
- W3082654025 created "2020-09-08" @default.
- W3082654025 creator A5004237346 @default.
- W3082654025 creator A5014582707 @default.
- W3082654025 creator A5024573751 @default.
- W3082654025 creator A5079201671 @default.
- W3082654025 creator A5080485119 @default.
- W3082654025 creator A5091827002 @default.
- W3082654025 date "2020-08-29" @default.
- W3082654025 modified "2023-10-15" @default.
- W3082654025 title "Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges" @default.
- W3082654025 cites W1488000644 @default.
- W3082654025 cites W1522465334 @default.
- W3082654025 cites W1555553634 @default.
- W3082654025 cites W1619537825 @default.
- W3082654025 cites W1757444495 @default.
- W3082654025 cites W1921422688 @default.
- W3082654025 cites W1942492061 @default.
- W3082654025 cites W1943300686 @default.
- W3082654025 cites W1967512987 @default.
- W3082654025 cites W1967517831 @default.
- W3082654025 cites W1967892265 @default.
- W3082654025 cites W1968013647 @default.
- W3082654025 cites W1968151924 @default.
- W3082654025 cites W1968174927 @default.
- W3082654025 cites W1978709366 @default.
- W3082654025 cites W1983393070 @default.
- W3082654025 cites W1985579610 @default.
- W3082654025 cites W1987446594 @default.
- W3082654025 cites W1993888933 @default.
- W3082654025 cites W2005555847 @default.
- W3082654025 cites W2007184765 @default.
- W3082654025 cites W2016830328 @default.
- W3082654025 cites W2024352108 @default.
- W3082654025 cites W2028128777 @default.
- W3082654025 cites W2043649175 @default.
- W3082654025 cites W2054937516 @default.
- W3082654025 cites W2056994982 @default.
- W3082654025 cites W2057463153 @default.
- W3082654025 cites W2057626036 @default.
- W3082654025 cites W2057680307 @default.
- W3082654025 cites W2060383229 @default.
- W3082654025 cites W2068155954 @default.
- W3082654025 cites W2069564189 @default.
- W3082654025 cites W2074165534 @default.
- W3082654025 cites W2075139424 @default.
- W3082654025 cites W2080585626 @default.
- W3082654025 cites W2081601480 @default.
- W3082654025 cites W2082708772 @default.
- W3082654025 cites W2089928288 @default.
- W3082654025 cites W2090186172 @default.
- W3082654025 cites W2090860241 @default.
- W3082654025 cites W2105435030 @default.
- W3082654025 cites W2107925822 @default.
- W3082654025 cites W2118796952 @default.
- W3082654025 cites W2126855868 @default.
- W3082654025 cites W2129702476 @default.
- W3082654025 cites W2134118606 @default.
- W3082654025 cites W2144491853 @default.
- W3082654025 cites W2145985838 @default.
- W3082654025 cites W2146059841 @default.
- W3082654025 cites W2151069914 @default.
- W3082654025 cites W2169808956 @default.
- W3082654025 cites W2172250118 @default.
- W3082654025 cites W2179454156 @default.
- W3082654025 cites W2329132457 @default.
- W3082654025 cites W2342423058 @default.
- W3082654025 cites W2400439118 @default.
- W3082654025 cites W2419639370 @default.
- W3082654025 cites W2525034031 @default.
- W3082654025 cites W2529226476 @default.
- W3082654025 cites W2549556456 @default.
- W3082654025 cites W2552868754 @default.
- W3082654025 cites W2576962736 @default.
- W3082654025 cites W2587836646 @default.
- W3082654025 cites W2599899418 @default.
- W3082654025 cites W2606654718 @default.
- W3082654025 cites W2609835530 @default.
- W3082654025 cites W2614019261 @default.
- W3082654025 cites W2619874848 @default.
- W3082654025 cites W2621546725 @default.
- W3082654025 cites W2725721905 @default.
- W3082654025 cites W2730231599 @default.
- W3082654025 cites W2748768234 @default.
- W3082654025 cites W2768556518 @default.
- W3082654025 cites W2768823259 @default.
- W3082654025 cites W2769895972 @default.
- W3082654025 cites W2771668512 @default.
- W3082654025 cites W2776787750 @default.
- W3082654025 cites W2787145330 @default.
- W3082654025 cites W2787301955 @default.
- W3082654025 cites W2789860721 @default.
- W3082654025 cites W2801641802 @default.
- W3082654025 cites W2805523469 @default.
- W3082654025 cites W2885192969 @default.
- W3082654025 cites W2888063816 @default.
- W3082654025 cites W2892758519 @default.
- W3082654025 cites W2893691711 @default.